Luke Halpern, Assistant Editor

Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.

The subcutaneous infusion is indicated for pediatric patients aged 6 to 17 years who weigh less than 60 kg.

New executive orders and legislation aim to lower prescription drug costs and enhance access to pharmacist services for seniors across the US.

Amy Duong, PharmD, BCACP, explains pharmacists' critical role in promoting chronic inflammatory demyelinating neuropathy (CIDP) treatment adherence and staying informed about new therapeutic developments.

In 3 phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

Results from a systematic review shed light on the role that obesity and overweight play in increasing the severity of symptoms in long COVID.

Patients with chronic kidney disease (CKD) and type 2 diabetes receiving both treatments had greater reductions in urinary albumin-to-creatinine ratio.

Mitomycin intravesical solution is the first FDA-approved treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Amy Duong, PharmD, BCACP, highlights pharmacists' essential responsibilities in chronic inflammatory demyelinating polyneuropathy (CIDP) patient care and immunoglobulin therapy management.

The approval of the tablet formulation of zanubrutinib covers all 5 approved indications of the Bruton tyrosine kinase inhibitor.

Pharmacists play a critical role in managing complex pericarditis cases.

Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).

Low uptake of vaccination to protect against invasive pneumococcal disease (IPD) was observed both before and after a pneumococcal-related hospitalization, with countless missed vaccination opportunities documented.

The restructuring of the Advisory Committee for Immunization Practices (ACIP) could impact recommendations for routine childhood and adult vaccinations.

Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option.

Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.

Subcutaneous immunoglobulin was found to elicit fewer viral infections compared with other routes of immunoglobulin replacement therapy, including intravenous immunoglobulin.

Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.

New products are poised to aid pharmacists in proper counting of inventory to prevent medication errors.

Implementation of the Plan-Do-Study-Act cycle in health system retail pharmacies significantly increased uptake of 20-valent pneumococcal conjugate vaccine among eligible adults.

Subcutaneous immunoglobulin (SCIg) is a hopeful alternative to intravenous immunoglobulin in patients with inflammatory myositis due to a lack of adverse effects and fewer financial constraints.

Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.

Results from the NeoADAURA trial demonstrate the sustained efficacy of osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small-cell lung cancer (NSCLC).

Amanda Gronniger, PharmD, CPh, BCCP, discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies.

The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial.

Chip Hailey, a 74-year-old pharmacist with hemophilia B, shares how gene therapy has liberated him from decades of challenging treatment and restored his independence.

The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.

Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk factors for severe COVID-19.